Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 11/20 | 0.34 |
| ▸ | BRAF | P15056 | 10/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776440 | 0.88 | CA2 (0.35) | CA2CA9RAF1BRAFMAPT | |
| SCHEMBL16776442 | 0.86 | CA2 (0.36) | CA2CA9RAF1BRAFNPC1 | |
| SCHEMBL16776322 | 0.81 | NPC1 (0.44) | CA2CA9RAF1BRAFNPC1 | |
| SCHEMBL16776165 | 0.80 | CA2 (0.43) | CA2CA9RAF1NPC1FYN | |
| SCHEMBL16776426 | 0.80 | CA2 (0.32) | CA2CA9RAF1BRAFTRPA1 | |
| SCHEMBL16776444 | 0.79 | MEN1 (0.34) | CASP6 | |
| SCHEMBL16775878 | 0.79 | KMO (0.38) | CA2CA9RAF1BRAFNPC1 | |
| SCHEMBL16776402 | 0.78 | NPC1 (0.42) | CA2CA9RAF1BRAFNPC1 | |
| SCHEMBL16776364 | 0.78 | CA2 (0.43) | CA2CA9RAF1BRAFNPC1 | |
| SCHEMBL16776367 | 0.78 | NPC1 (0.44) | CA2CA9RAF1BRAFNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA2 4253/4885CA9 4248/4885RAF1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.